🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07792044
Enrolling by invitation Not applicable

Effect of Optimal Biological Volume Bupivacaine Liposome Interscalene Brachial Plexus Block on Postoperative Analgesia After Shoulder Arthroscopy

NCT07792044 · tracked via the Priya Life Science China tracker
Sponsor
Affiliated Hospital of Jiaxing University
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-28

Condition(s) studied

Pain and Diaphragmatic Dysfunction After Shoulder Arthroscopy

Investigational drug(s) / intervention(s)

OBV bupivacaine liposome groupStandard dose bupivacaine liposome group

OBV bupivacaine liposome group: Following our preliminary study protocol, 13 mL of liposomal bupivacaine (derived from the 20 mL/266 mg commercial formulation) is aspirated and further diluted with 0.9% sodium chloride injection to a final total volume of 53 mL while maintaining the fixed total dose of 266 mg. This diluted preparation is then combined with 2 mL of 0.5% conventional bupivacaine, and the resultant 55 mL mixture is administered to perform interscalene brachial plexus block prior to surgical incision.

Standard dose bupivacaine liposome group: Following the recommendations in published literature and the approved product labeling, 10 mL of liposomal bupivacaine (20 mL/266 mg formulation) is aspirated, combined with 2 mL of 0.5% conventional bupivacaine, diluted to a final total volume of 15 mL with 0.9% sodium chloride injection, and administered to perform ultrasound-guided interscalene

Study summary

This study aims to evaluate whether 15ml/75mg low-dose bupivacaine liposome is non-inferior to 15ml/133mg standard-dose bupivacaine liposome for postoperative analgesia in interscalene brachial plexus block during arthroscopic shoulder surgery, through a single-center, prospective, double-blind, non-inferiority randomized controlled clinical trial. It will also assess whether 15ml/75mg low-dose bupivacaine liposome is superior to 15ml/133mg standard-dose bupivacaine liposome in terms of diaphragmatic excursion, pulmonary function, duration of block effect, and nerve block-related adverse reactions during interscalene brachial plexus block.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 years or older. * ASA classification I-III. * Arthroscopic shoulder rotator cuff repair, capsular plication, acromioplasty, synovectomy, etc. Exclusion Criteria: * Have a history of lung disease. * Coagulation dysfunction or coagulopathy. * History of allergy to local anesthetics. * infection or lesions at the block site; or history of cervical spine disease. * pregnancy. * Refusal to participate in the study or inability to communicate. * Long-term use of opioids. * Body mass index \>35 kg/m2 * Previous history of nerve injury, paralysis, or paresis;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Jiaxing University Affiliated Hospital Jiaxing Zhejiang

More Affiliated Hospital of Jiaxing University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07792044 on ClinicalTrials.gov ↗ ← All trials in China